YOU SEARCHED BY...
How a Biologics CDMO Adds Value to mAbs Development & Manufacturing Programs
More Content From How a Biologics CDMO Adds Value to mAbs Development & Manufacturing Programs
-
A CDMO's Mission To Empower Emerging Biotechs
A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.Sponsored Content Released on 01.15.2024
-
Does Your Biologics CDMO Truly Have A Culture Of Quality?
What is a culture of quality, and how do you know if a biologics CDMO can earnestly make this claim?Sponsored Content Released on 01.15.2024
-
The Bioanalytical Development Journey
As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development.Sponsored Content Released on 01.15.2024
-
ABC: Analytics For Biomanufacturing
Samir Lakhashe, Director, Bioanalytical Sciences, discusses assay categorization, the company's growing toolbox, predictions for the future, and more.Sponsored Content Released on 01.15.2024
-
Report: Trends Shaping the Future of Emerging Biotechs
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.White Papers / Tech Papers Released on 01.11.2024
-
An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market
The demand for biologic drugs continues to grow at a steady 12–14% annually.Sponsored Content Released on 01.11.2024
-
Why Process Matters: How Biologics Process Development Can Accelerate Your Path To Market
Biologics process development is an active undertaking that seeks continuous improvement along the entire length of the drug development timeline.Company Blog Released on 01.11.2024
-
What Does It Take To Be A Biologics CDMO That Can Serve Today's Mammalian Clinical Mfg Needs?
Clinical manufacturing of cGMP-compliant mammalian cell culture processes is a complex and resource-intensive effort that presents several challenges.Company Blog Released on 01.11.2024
-
Facility Overview: Scorpius BioManufacturing
Scorpius BioManufacturing is a boutique, US-based biologics CDMO with available capacity for mammalian, cell therapy, and microbial-based programs.Videos Released on 01.10.2024
-
Top 6 Questions To Ask When Evaluating A Biologics CDMO
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.Company Blog Released on 01.10.2024
-
5 New Questions to Ask Before Signing with a Biologics CDMO
The value biologics CDMOs provide their innovator customers has changed radically in recent years, presenting new questions that must be answered.Company Blog Released on 01.10.2024
-
Evaluating Biologics CDMOs: Tips For Crafting An RFP
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.Company Blog Released on 01.10.2024
-
How To Select The Right Biologics CDMO Partner
When selecting a biologics CDMO partner—whether you need mammalian or microbial capabilities—the decision-making process follows a similar process.Company Blog Released on 01.10.2024
-
Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197
The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, and more.News Releases Released on 01.10.2024
-
FinaBio’s Search for a CDMO to Support Affordable Conjugate Vaccines
Why Fina Biosolutions partnered with Scorpius Biomanufacturing for cGMP production of Ecocrm® (CRM197)Case Studies Released on 01.10.2024
